Natco Pharma Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/shrf2qtnqs35r8r0pviqvhol.pdf

Key Takeaways


GLP-1 & India Growth

Rajeev Nannapaneni: "India is actually a very tricky market. I'm positive about the semaglutide launch, but I think it will be extremely competitive. I think my expectation is that there are going to be a lot of generics."

Base Business & Diversification


Para IV Pipeline & U.S. Launches


M&A & Capital Allocation

Rajeev Nannapaneni: "I would like to preserve my cash for another transaction similar to size of Adcock. I wouldn't want to do a buyback at this time."

eGenesis & NCE Optionality

Rajeev Nannapaneni: "This is probably the most disruptive thing that's going to happen in medicine... If you ask me, this is an idea of the decade."

Regulatory & Operational Updates

Rajeev Nannapaneni: "I think the returns outside India are much better than India. I think that has always been my take. And I mean, obviously, I've been against the grain in the conventional thinking that people have been more comfortable doing acquisitions within India because it's a more certain environment and the variables are more controllable. But having said that, I believe that going out, the return is much higher."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue~₹4,200–₹4,300 crores, with Q4 at ₹700–₹750 croresFY26 (March 2026)
FY26 PAT~₹1,280–₹1,300 crores based on 9-month PAT of ~₹1,150 croresFY26 (March 2026)
GLP-1 (Ozempic) approvalPending at DCGI, SEZ clearance receivedFebruary 2026
GLP-1 (Ozempic) launchDiabetes strength launch when market opensPost-March 2026
Wegovy filingClinical trial completion, then filing for approvalShortly (no date)
Crop Health Sciences de-mergerProcess completion8–9 months (~Oct/Nov 2026)
Large M&A closureAt least 1–2 large transactionsCalendar year 2026
Non-Para IV ANDA launchesApprovals expected, launches to followApril–June 2026 quarter
Complex generic filings~8 products targeted, 4–5 already filedFY26
eGenesis home-run scenarioTrial reaches ~25–30 patientsNext 2–3 years
Olaparib clarityTentative approval and exclusivity detailsNext few months
Semaglutide market guidanceMore clarity on uptake and guidanceMay 2026 (annual audited numbers)

Key Metrics

MetricQ3 FY26
Consolidated total revenue₹705.4 cr, vs ₹651.1 cr in Q3 FY25
EBITDA₹216.8 cr, margin at 30.7%
Net profit (consolidated)₹151.3 cr
Revenue from Adcock Ingram (H1 FY26)₹2,464 cr, profit after tax of ₹198 cr
Adcock profit share reflected in NATCO books₹10.9 cr, after one-time amortization of ₹18.75 cr on ₹29.65 cr profit pick-up at 35.75%
Net cash position~₹2,500 cr
Interim dividend₹1.5 per equity share of ₹2 face value
Revlimid revenue₹0, no Revlimid in the quarter
Export formulations YoY uptick~₹135 cr
Subsidiary sales₹177 cr out of total ₹705 cr
R&D spend~8% of sales (rough estimate)
Total MR strength~600, with ~350–400 allocated to semaglutide
FY26 revenue guidance~₹4,200–₹4,300 cr, with 9M at ₹3,559 cr and Q4 expected at ₹700–₹750 cr
FY26 PAT guidance~₹1,280–₹1,300 cr, with 9M at ~₹1,150 cr and Q4 expected at ~₹150 cr
Annual Adcock amortization expected~₹10–₹14 cr per year, roughly ₹3 cr per quarter